Its primary application is in multiple myeloma (MM) where CD38 is highly and uniformly expressed, but it is also being evaluated in lymphomas, including diffuse large B cell lymphoma, FL and mantle cell lymphoma, in AML and in ALL (87, 173). Here, CD38 is linked to Miyoshi myopathy.